Human medicines European public assessment report (EPAR): Champix, varenicline, Tobacco Use Cessation, Date of authorisation: 25/09/2006, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Venclyxto, venetoclax, Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 04/12/2016, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Comirnaty, tozinameran,riltozinameran and tozinameran,famtozinameran and tozinameran,COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 virus infection, Date of authorisation: 21/12/2020, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Fycompa, perampanel, Epilepsies, Partial, Date of authorisation: 23/07/2012, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Lupus Erythematosus, Systemic, Date of authorisation: 13/07/2011, Revision: 31, Status: Authorised

Methodology Working Party stakeholder interaction meeting, Online, from 07/12/2023 to 07/12/2023

EMA recommends approval of adapted Nuvaxovid COVID-19 vaccine targeting Omicron XBB.1.5

Draft revised consolidated 3-year work plan for the Methodology Working Party (MWP)

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms, Date of authorisation: 17/07/2015, Revision: 54, Status: Authorised

Human medicines European public assessment report (EPAR): Karvezide, irbesartan,hydrochlorothiazide, Hypertension, Date of authorisation: 16/10/1998, Revision: 47, Status: Authorised